These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29384209)

  • 1. Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
    Yacoub W; Williet N; Pouillon L; Di-Bernado T; De Carvalho Bittencourt M; Nancey S; Lopez A; Paul S; Zallot C; Roblin X; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2018 Apr; 47(7):906-912. PubMed ID: 29384209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months.
    Williet N; Boschetti G; Fovet M; Di Bernado T; Claudez P; Del Tedesco E; Jarlot C; Rinaldi L; Berger A; Phelip JM; Flourie B; Nancey S; Paul S; Roblin X
    Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1750-1757.e3. PubMed ID: 27890854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
    Singh S; Dulai PS; Vande Casteele N; Battat R; Fumery M; Boland BS; Sandborn WJ
    Aliment Pharmacol Ther; 2019 Oct; 50(8):848-857. PubMed ID: 31483522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease.
    Guidi L; Pugliese D; Panici Tonucci T; Bertani L; Costa F; Privitera G; Tolusso B; Di Mario C; Albano E; Tapete G; Gremese E; Papa A; Gasbarrini A; Rapaccini GL; Armuzzi A
    United European Gastroenterol J; 2019 Nov; 7(9):1189-1197. PubMed ID: 31700632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease.
    Al-Bawardy B; Ramos GP; Willrich MAV; Jenkins SM; Park SH; Aniwan S; Schoenoff SA; Bruining DH; Papadakis KA; Raffals L; Tremaine WJ; Loftus EV
    Inflamm Bowel Dis; 2019 Feb; 25(3):580-586. PubMed ID: 30165638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis.
    Pouillon L; Rousseau H; Busby-Venner H; De Carvalho Bittencourt M; Choukour M; Gauchotte G; Zallot C; Danese S; Baumann C; Peyrin-Biroulet L
    J Crohns Colitis; 2019 Aug; 13(8):970-975. PubMed ID: 30698684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.
    Hanžel J; Sever N; Ferkolj I; Štabuc B; Smrekar N; Kurent T; Koželj M; Novak G; Compernolle G; Tops S; Gils A; Drobne D
    United European Gastroenterol J; 2019 Jul; 7(6):741-749. PubMed ID: 31316778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.
    Dreesen E; Verstockt B; Bian S; de Bruyn M; Compernolle G; Tops S; Noman M; Van Assche G; Ferrante M; Gils A; Vermeire S
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1937-1946.e8. PubMed ID: 29704680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
    Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
    Löwenberg M; Vermeire S; Mostafavi N; Hoentjen F; Franchimont D; Bossuyt P; Hindryckx P; Rispens T; de Vries A; van der Woude CJ; Berends S; Ambarus CA; Mathot R; Clasquin E; Baert F; D'Haens G
    Gastroenterology; 2019 Oct; 157(4):997-1006.e6. PubMed ID: 31175865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease.
    Steenholdt C; Lorentsen RD; Petersen PN; Widigson ES; Kloft C; Klaasen RA; Brynskov J
    J Gastroenterol Hepatol; 2024 Jun; 39(6):1088-1098. PubMed ID: 38380724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.
    Liefferinckx C; Minsart C; Cremer A; Amininejad L; Tafciu V; Quertinmont E; Tops S; Devière J; Gils A; van Gossum A; Franchimont D
    Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):478-485. PubMed ID: 30672828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview.
    Pouillon L; Vermeire S; Bossuyt P
    BMC Med; 2019 May; 17(1):89. PubMed ID: 31064370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.
    Ungaro RC; Yarur A; Jossen J; Phan BL; Chefitz E; Sehgal P; Kamal K; Bruss A; Beniwal-Patel P; Fox C; Patel A; Bahur B; Jain A; Stein D; Naik S; Dubinsky MC
    J Crohns Colitis; 2019 Aug; 13(8):963-969. PubMed ID: 31087100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease.
    Rowland P; McNicol M; Kiel A; Maltz RM; Donegan A; Dotson JL; Michel HK; Boyle B
    J Pediatr Gastroenterol Nutr; 2024 Apr; 78(4):853-861. PubMed ID: 38270212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting.
    Hemming-Harlo M; Merras-Salmio L; Nikkonen A; Kolho KL
    Eur J Pediatr; 2024 Jan; 183(1):313-322. PubMed ID: 37878072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
    Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
    J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases.
    Yarur AJ; Bruss A; Naik S; Beniwal-Patel P; Fox C; Jain A; Berens B; Patel A; Ungaro R; Bahur B; Dubinsky M; Stein DJ
    Dig Dis Sci; 2019 Jun; 64(6):1651-1659. PubMed ID: 30835029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
    Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.